359 related articles for article (PubMed ID: 24402184)
1. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
2. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
4. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
5. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
8. Current status of immunological approaches for the treatment of prostate cancer.
Drake CG; Antonarakis ES
Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Thara E; Dorff TB; Pinski JK; Quinn DI
Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer immunotherapy.
May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
[TBL] [Abstract][Full Text] [Related]
13. Integration of immunotherapy into the management of advanced prostate cancer.
Kantoff P; Higano CS
Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
[TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
Carballido E; Fishman M
Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
[TBL] [Abstract][Full Text] [Related]
15. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T for the treatment of advanced prostate cancer.
Frohlich MW
Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
[TBL] [Abstract][Full Text] [Related]
17. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
[TBL] [Abstract][Full Text] [Related]
18. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
20. Current status of immunological therapies for prostate cancer.
Antonarakis ES; Drake CG
Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
